Experts from Nottingham's two universities have teamed up to adapt a cancer treatment for use in the fight against Covid-19.
They are collaborating with Scancell Holdings, a developer of novel immunotherapies for cancer, to move the project forward.
Virologists at the University of Nottingham’s Centre for Research on Global Virus Infections have identified parts of the novel coronavirus they hope will generate an immune response that will prevent future infection.
This information is being used by Scancell to design DNA-based vaccines to allow easy and effective delivery of the virus vaccine into humans to produce virus-killing antibodies and cells.
The project builds on Scancell’s success with its lead ImmunoBody cancer vaccine to treat patients suffering from malignant melanoma.
Although other vaccines may have reached the clinic earlier, the team believe that the combined T cell and antibody approach will give more potent and long-lasting responses, ultimately leading to better protection.
We are sharing news for link source - Nottingham Post
All images and copyright remains with news source